Drug recall · October 7, 2026
Ranolazine Extended-Release Tablets recall
Why: Failed Dissolution Specifications: below specification
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle, Rx Only, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807. NDC: 27241-126-02
- Lots / codes
Lot: DJ25134, Exp 11/30/2028
- Company
- Ajanta Pharma USA Inc, Bridgewater, NJ
- Distribution
- Nationwide in the US.
- Initiated
- September 17, 2026 · Voluntary: Firm initiated
- Classified
- October 6, 2026
- Reported
- October 7, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Ranolazine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.